Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have favorable cardiovascular outcomes in patients with diabetes. However, whether SGLT2i can improve obesity-related cardiac dysfunction is unknown. Sestrin2 is a novel stress-inducible protein that regulates AMPK–mammalian target of rapamycin (mTOR) and suppresses oxidative damage. The aim of this study was to determine whether empagliflozin (EMPA) improves obesity-related cardiac dysfunction via regulating Sestrin2-mediated pathways in diet-induced obesity. C57BL/6J mice and Sestrin2 knockout mice were fed a high-fat diet (HFD) for 12 weeks and then treated with or without EMPA (10 mg/kg) for 8 weeks. Treating HFD-fed C57BL/6J mice with EMPA reduced body weight and whole-body fat and improved metabolic disorders. Furthermore, EMPA improved myocardial hypertrophy/fibrosis and cardiac function and reduced cardiac fat accumulation and mitochondrial injury. Additionally, EMPA significantly augmented Sestrin2 levels and increased AMPK and endothelial nitric oxide synthase phosphorylation, but inhibited Akt and mTOR phosphorylation. These beneficial effects were partially attenuated in HFD-fed Sestrin2 knockout mice. Intriguingly, EMPA treatment enhanced the Nrf2/HO-1–mediated oxidative stress response, suggesting antioxidant and anti-inflammatory activity. Thus, EMPA improved obesity-related cardiac dysfunction via regulating Sestrin2-mediated AMPK-mTOR signaling and maintaining redox homeostasis. These findings provide a novel mechanism for the cardiovascular protection of SGLT2i in obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, several antifibrotic interventions -including traditional Chinese medicinal (TCM) compounds and pharmaceutical agents such as metformin, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is)- promote restorative macrophage polarization, at least in part, through activation of AMPK-dependent pathways and enhance hepatic autophagy (34, 39, 41–44).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [43]
Citations
Cites
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 2×
“Sesn2 also promotes phosphorylation of AMPK through its upstream kinase liver kinase B1 (LKB1)– dependent way and mediates genotoxic stress-induced AMPK activation and mTOR inhibition (12,13).”
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Self-citationZhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“We found that EMPA treatment triggered eNOS phosphorylation at Ser(1177), indicating endothelial-protective effects of EMPA, which is consistent with a previous study (42).”
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Bae, S. H., Sung, S. H., Oh, S. Y., Lim, J. M., Lee, S. K., Park, Y. N., Lee, H. E., Kang, D., & Rhee, S. G. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.002 · Cited by 492 · cited 1×
“(41) reported that Sesn2 induces Nrf2 activation by enhancing the autophagic degradation of Keap1.”
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Cited by
Items 101–193 of 193
Potential Roles of Sestrin2 in Alzheimer’s Disease: Antioxidation, Autophagy Promotion, and Beyond
Chen, S., Yang, J., Hsieh, Y.-H., Lin, T., Lin, Y., Chao, A., & Yang, D. (2021) · Biomedicines · doi:10.3390/biomedicines9101308 · Cited by 13
Zhang, Y., Zhang, Z., Li, C., Tang, D., & Dai, Y. (2022) · Molecular Omics · doi:10.1039/d2mo00036a · Cited by 13
Gao, T., Wang, J., Xiao, M., Wang, J., Wang, S., Tang, Y., Zhang, J., Lu, G., Guo, H., Guo, Y., et al. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0156 · Cited by 13
Self-citationResearch Progress of Antioxidant Nanomaterials for Acute Pancreatitis
Zheng, X., Zhao, J., Wang, S., & Hu, L. (2022) · Molecules · doi:10.3390/molecules27217238 · Cited by 13
Göpel, S., Adingupu, D. D., Wang, J., Semenova, E., Behrendt, M., Jansson‐Löfmark, R., Ahlström, C., Jönsson‐Rylander, A., Gopaul, V. S., ESTERLINE, R. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02491-w · Cited by 14
Wang, T., Hu, W., Niu, Y., Liu, S., & Fu, L. (2021) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2021-0241 · Cited by 12
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Jing, Y., Yang, R., Chen, W., & Ye, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.898718 · Cited by 12
Nazari‐Khanamiri, F., Jafari, A., Esmaeilzadeh, Z., & Ghasemnejad‐Berenji, M. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02958-2 · Cited by 11
Li, X., Wang, Z., Mouton, A. J., Omoto, A. C. M., da Silva, A. A., do Carmo, J. M., Li, J., & Hall, J. E. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035193 · Cited by 16
Self-citationTian, Z., Yan, B., Luo, W., Gui, D.-D., Zhou, K., Tian, K.-J., Ma, Y., Zhou, Z., & Jiang, Z. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.019 · Cited by 12
Cotrin, J. C., de Souza, G. S. M., Petito‐da‐Silva, T. I., Cardoso, L. E. M., Souza‐Mello, V., & Barbosa‐da‐Silva, S. (2022) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2022/8861911 · Cited by 11
Kuang, Z., Hou, N., Kan, C., Han, F., Qiu, H., & Sun, X. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03355-6 · Cited by 10
Self-citationXiao, T., & Wei, J. (2024) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320241234741 · Cited by 11
Sestrin2 remedies neuroinflammatory response by inhibiting A1 astrocyte conversion via autophagy
Pan, Z., Yu, X., Wang, W., Shen, K., Chen, J., Zhang, Y., & Huang, R. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16126 · Cited by 11
Mao, E.-W., Cheng, X., Li, W., Kan, C., Huang, N., Wang, H., Hou, N., & Sun, X. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i36.11156 · Cited by 11
Self-citationA metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice
Chen, X., Chen, S., Ren, Q., Niu, S., Yue, L., Pan, X., Li, Z., Zhu, R., Jia, Z., Chen, X., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.06.091 · Cited by 9
Muscular Sestrins: Roles in Exercise Physiology and Stress Resistance
Hwang, I., & Kim, M. (2023) · Biomolecules · doi:10.3390/biom13050722 · Cited by 10
Sestrin2 in diabetes and diabetic complications
Zhang, X., Luo, Z., Li, J., Lin, Y., Yu, L., & Li, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274686 · Cited by 12
Self-citationPriscilla, L., Yoo, C., Jang, S., Park, S., Lim, G., Kim, T., & Lee, D. Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.01.027 · Cited by 13
Wang, H., Xi, J., Zhang, Z., Li, J., Guo, L., Li, N., Sun, Y., Li, X., & Han, X. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001314 · Cited by 10
Self-citationRole of dysfunctional peri-organ adipose tissue in metabolic disease
Zhang, K., Zhang, J., Kan, C., Tian, H., Ma, Y., Huang, N., Han, F., Hou, N., & Sun, X. (2023) · Biochimie · doi:10.1016/j.biochi.2023.03.015 · Cited by 10
Self-citationProtective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells
Song, M., Cui, W., Lee, C.-G., Cui, R., Son, Y. H., Kim, Y. H., Kim, Y., Kim, H. J., Choi, S., KANG, Y. Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228646 · Cited by 9
Mitochondrial glycerol 3-phosphate dehydrogenase deficiency exacerbates lipotoxic cardiomyopathy
Qu, H., Liu, X., Zhu, J., He, N., He, Q., Zhang, L., Wang, Y., Gong, X., Xiong, X., Liu, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109796 · Cited by 7
Hou, J., Ren, L., Hou, Q., Jia, X., Mei, Z., Xu, J., Yang, Z., Li, Y., & Yan, C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1388337 · Cited by 14
Role of natural products in cardiovascular disease
Dong, Q., Dai, G., Quan, N., & Tong, Q. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05048-3 · Cited by 11
Emara, A. M., Bendary, A. S. E., Ahmed, L. M., & Okda, H. I. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03663-2 · Cited by 13
Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class
Hopkins, S. E., Baqai, F., Gajagowni, S., & Hickey, G. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251323428 · Cited by 9
Sun, H., Wang, J., Kuang, H., Fan, G., & Yang, X. (2025) · Food Chemistry X · doi:10.1016/j.fochx.2025.102865 · Cited by 7
Wen, J., Liu, G., Liu, M., Wang, H., Wan, Y., Yao, Z., Gao, N., Sun, Y., & Zhu, L. Y. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2293595 · Cited by 7
Farnesoid X Receptor (FXR) Regulates mTORC1 Signaling and Autophagy by Inhibiting SESN2 Expression
Wang, G., Chen, L., Qin, S., Geng, H., Xia, C., Zheng, Y., Lei, X., Zhang, J., Wu, S., Yao, J., et al. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200517 · Cited by 7
Self-citationWang, J., Du, H., Sun, Q., Wan, W., & Zhang, H. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03604-1 · Cited by 6
LDHA contributes to nicotine induced cardiac fibrosis through autophagy flux impairment
Wu, H., Du, J.-M., Liu, P., Meng, F.-L., Li, Y., Li, W., Wang, S.-X., Du, N.-L., Zhang, L., Zhang, L., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112338 · Cited by 6
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Yerra, V. G., & Connelly, K. A. (2024) · Physiology · doi:10.1152/physiol.00008.2024 · Cited by 7
Reis‐Barbosa, P. H., & Mandarim‐de‐Lacerda, C. A. (2024) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.13024 · Cited by 6
Zhang, K., Kan, C., Han, F., Zhang, J., & Sun, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i2.137 · Cited by 7
Self-citationSGLT2 inhibitors: Do they have antiarrhythmic properties?
Caballero, R., Tamargo, J. L., & Delpón, E. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108973 · Cited by 7
Effects of empagliflozin against indomethacin induced gastric mucosa
Taşkaldıran, I., Kuşkonmaz, Ş. M., Çelepli, P., Hücümenoğlu, S., Nural, C., Erel, Ö., & Çulha, C. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03425-4 · Cited by 5
Song, X., Han, L., Lin, X., Tian, M., Sun, F., & Feng, B. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-685 · Cited by 5
Choi, W. J., Kim, M. H., Park, N., Chung, J. Y., Park, S. J., & Yang, W. M. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100948 · Cited by 7
Zhang, L., Kan, C., Shi, J., Qiu, H., Zhang, J., Ding, W., Xu, L., Zhang, K., Guo, Z., Hou, N., et al. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00834-8 · Cited by 5
Self-citationEmpagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism
Yue, L., Wang, Y., Wang, C., Niu, S., Dong, X., Guan, Y., & Chen, S. (2024) · Open Medicine · doi:10.1515/med-2024-1012 · Cited by 5
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
Self-citationHushmandi, K., Salarizadeh, N., Einollahi, B., Izadi, M., Doosti, P., Behzadnia, M. J., Cho, W. C., Yousefi, T., Khoshnazar, S. M., Alimohammadi, M., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01824-0 · Cited by 4
Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
Gao, Z., Bao, J., Hu, Y., Tu, J., Ye, L., & Wang, L. (2023) · Current Drug Targets · doi:10.2174/1389450124666230907115831 · Cited by 5
Liébana, L. R. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.3.art3 · Cited by 5
Sestrins as Biomarkers of Cellular Stress and Human Disease
Haidurov, A., & Budanov, A. V. (2026) · Cells · doi:10.3390/cells15070651 · Cited by 4
Soares, R. R., Viggiani, L. F., Filho, J. M. R., & Joviano‐Santos, J. V. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111229 · Cited by 5
Liu, L., Ma, J., Wei, Z., Yang, Y., Liu, Z., Li, D., Yu, X., Fan, Y., Wang, F., & Wan, Y. (2023) · The FASEB Journal · doi:10.1096/fj.202300822r · Cited by 4
Theodoropoulou, T., Mourouzis, I. S., Katsaouni, A., Pantos, C. I., Tsioufis, K. P., & Toutouzas, K. P. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177985 · Cited by 5
Yang, W., Chen, X., Wang, D., Liu, L., Ma, H., Wang, T., Zhu, H., Wang, J., Ma, T., Cao, P., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157621 · Cited by 5
12,13-diHOME ameliorates MASLD by regulating Sestrin2-mediated AMPK/ULK1/Lipophagy in obese mice
ZHANG, K., Kan, C., Qiu, H., Shi, J., Chen, J., Zheng, T., Zhang, J., Ma, Y., Sheng, S., Hou, N., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168186 · Cited by 3
Self-citationZaini, L. M., Kartasasmita, A., Gondhowiardjo, T. D., Syukri, M., & Lesmana, R. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2111302 · Cited by 3
The latest emerging drugs for the treatment of diabetic cardiomyopathy
Li, M., Liu, L., Zhang, C., Deng, L., Zhong, Y., Liao, B., Li, X., Wan, Y., & Feng, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2347468 · Cited by 3
Self-citationLi, Y., Zhang, Z., Zhang, Z., Zheng, N., & Ding, X. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31264 · Cited by 4
Feng, S., Chen, R., Huang, H., Ong, M., Jiang, J., Cui, J., & Ling, Q. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17540-1 · Cited by 4
TorS ‐ Reframing a rational for type 2 diabetes treatment
Bar‐Tana, J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3712 · Cited by 2
Song, X., He, W., Su, T., Li, C.-J., Jiang, L., Huang, S.-Q., Li, S.-H., Guo, Z., & Zhang, B. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.02.012 · Cited by 2
Николаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas
Alausa, A. O., Victor, U. C., Celestine, U. O., Eweje, I. A., Balogun, T. A., Adeyemi, R. O., Olatinwo, M., Ogunlana, A. T., Oladipo, O. O., & Olaleke, B. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100133 · Cited by 2
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
Sestrin2 at the crossroads of cardiovascular disease and diabetes: A comprehensive review
Sivakumar, R., Senghor, K. A. A., Vinodhini, V. M., & Kumar, J. S. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100558 · Cited by 1
Mooradian, A. D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00685-x · Cited by 1
SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
Patel, R., & Oroszi, T. L. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.1512027 · Cited by 1
Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review
Luo, H., Zhang, N., Liu, Y., Chen, P., Duan, P., Lou, X., Yu, H., Lei, Q., Zhao, G., Wang, M., et al. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611319744250116092707 · Cited by 1
Obesity accelerates aging: Mechanisms and therapeutic implications
Zhang, R., Liu, L., Shi, X., & Ren, Y. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101980 · Cited by 2
Semaglutide’s Impact on Kidney Health in Obese Mice: A Metabolomics Study
Eriksson, J., & Lindgren, M. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/5whbt71l9k · Cited by 1
Elshazly, S. M., Mahmoud, N. M., Ahmed, G. A.-R., El-shaarawy, F. F., & Ibrahim, S. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117641 · Cited by 1
Lee, J., Park, S., Kim, E., Park, J.-Y., Rhee, M., Hughes, J. W., Ko, S., Kwon, O., & Lee, E. Y. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e44 · Cited by 2
Sabourin, S., Thrasher, C. A., Smith, R. M., Belanger, K., Thibodeau, B., Abi‐Ghanem, C., Lafrican, J. J., Camon, C., Kelly, R. D., Richard, R., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03719-0 · Cited by 3
Focusing on Diastolic Dysfunction to Achieve Consensus With the Term Diabetic Cardiomyopathy
King, A. N., & Ussher, J. R. (2026) · Diabetes · doi:10.2337/dbi26-0002 · Cited by 1
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Büyükaydın, B. (2023) · International journal of medical biochemistry/International journal of medical biochemistry : · doi:10.14744/ijmb.2023.20053 · Cited by 2
GLP-1RA Combined with SGLT2 Inhibitors for the Treatment of Diabetic Kidney Disease: A Meta Analysis
郭, 莹. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112543
Effects of Pharmacoacupuncture for Obesity: A Systematic Review and Meta-Analysis
Kim, S., Song, M., Chung, W., Kim, H., Shin, W., Kang, J., Seo, J., Seo, S., Yu, S. H., Lim, J.-H., et al. (2023) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2023.23.2.112
Zhu, Y., Xu, F., Li, B., & Ren, T. (2024) · Journal of Food Biochemistry · doi:10.1155/jfbc/2345681
Zhang, J., Huang, L., Zheng, Y., Yang, J. Y., Wu, X., & He, J.-D. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70056
Self-citationJaiswal, S., Rajwade, D., Mehta, P., & Kumar, H. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00492
Sawalha, K., Alamat, L., Rana, A., Bruich, L., & Candales, A. L. (2025) · Cureus · doi:10.7759/cureus.97446
Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy
Chan, J. S. F., Dakhili, S. A. T., Wu, N. R., Stenlund, M. J., King, A. N., Dong, L., Mangra-Bala, I. A., Shafaati, T., Ferrari, S. R., Greenwell, A. A., et al. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100825 · Cited by 3
Bogomolov, A. N., Николаевна, К. О., Kozlov, K. L., & Golikova, E. N. (2025) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2025-546-556 · Cited by 1
Additional file 1 of Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21341089
Additional file 2 of Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21341092
Perelman, M. G., Brzezinski, R. Y., Banai, S., Wolf, I., & Laufer‐Perl, M. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042404
Yang, Y., Zhou, W., Yang, M., Tang, S. C. W., & Liu, B.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800868 · Cited by 1
Hu, X., Yang, X., Zhu, Z., Yang, Z., Wang, P., Wu, M., & Zhang, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1768784
Yahia, O. A., Elzeiny, D. A., Elshenawy, D. S. A., Elsukary, A. E., Abdel-Halim, N. H. M., Elsherbini, S., & Hassan, Y. F. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124470
Lei, Y., GAO, C., Zhao, X., Huang, W., Jiang, C. Q., Wu, Q., Law, B. Y. K., & Xu, Y. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61187-9
Luo, C., Luo, W., Zheng, T., Wang, P., Cao, L., Luan, H., Song, Y., Li, X. B., & Tian, G. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048155
Self-citationTsujikawa, L. M., Carestia, A., Wasiak, S., Sarsons, C. D., Jahagirdar, R., Azhar, S., Gilham, D., Li, D., Fu, L., Johansson, J. O., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14071647
Farsi, F., Sarvi, D. G., Abbasi, M., & Hasani‐Ranjbar, S. (2026) · International Journal of Endocrinology · doi:10.1155/ije/5558442
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
Sestrin2 mitigates obesity-associated HFpEF via adaptive IRE1α-XBP1 signaling and redox regulation
Zhang, K., Kan, C., Zhang, J., Ma, Y., Qiu, H., Shi, J., Sheng, S., Xiong, G., Hou, N., Han, F., et al. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026168
Self-citationKha, P. T., Nguyen, H. T. T., Garcia, M. V. F., Yoon, C., Indarua, M. A. S., Yun, H. R., Vu, T. T., Kim, H. K., & Han, J. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.1247
Metadata
- Authors
- Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J.
- Affiliations
- Weifang Medical University (CN)
- Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, MS
- University of Mississippi Medical Center (US)
- University of South Florida (US)
- University of California, Davis (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-31
- Volume
- 69
- Issue
- 6
- Pages
- 1292-1305
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3014209855
- Cited by
- 193
- References
- 46
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 39 · 2023: 36 · 2022: 43 · 2021: 29 · 2020: 7
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-17-IBS-296)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- empagliflozin, SGLT2 inhibitors, obesity, cardiac dysfunction, Sestrin2, AMPK/mTOR signaling, redox homeostasis, oxidative stress, Nrf2/HO-1 pathway, endothelial nitric oxide synthase, cardiac hypertrophy, myocardial fibrosis, mitochondrial injury, high-fat diet, cardioprotection
- MeSH terms
- Sestrins, Adenylate Kinase, Animals, Benzhydryl Compounds, Dietary Fats, Gene Expression Regulation, Glucosides, Heart Diseases, Homeostasis, Obesity, Oxidation-Reduction, Peroxidases, Signal Transduction, Mice, TOR Serine-Threonine Kinases, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.